Genomes and Genes
Summary: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Articles from Journal RESEARCH
Articles from Journal RESEARCH2
Publications374 found, 100 shown here
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag
Plexxikon Inc, 91 Bolivar Drive, Berkeley, California 94710, USA
Nature 467:596-9. 2010..The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are dependent on the RAF/MEK/ERK pathway, offered hope that ..
- Melanoma genome sequencing reveals frequent PREX2 mutationsMichael F Berger
The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
Nature 485:502-6. 2012b>Melanoma is notable for its metastatic propensity, lethality in the advanced setting and association with ultraviolet exposure early in life...
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, USA
N Engl J Med 367:1694-703. 2012..To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor...
- Mutations of the BRAF gene in human cancerHelen Davies
Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA, UK
Nature 417:949-54. 2002..As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
- Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
N Engl J Med 364:2507-16. 2011Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationRamin Nazarian
Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
Nature 468:973-7. 2010..We used PLX4032-resistant sub-lines artificially derived from B-RAF(V600E)-positive melanoma cell lines and validated key findings in PLX4032-resistant tumours and tumour-matched, short-term cultures from ..
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman
Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
N Engl J Med 366:707-14. 2012..The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.
- TERT promoter mutations in familial and sporadic melanomaSusanne Horn
Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
Science 339:959-61. 2013Cutaneous melanoma occurs in both familial and sporadic forms...
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen
Broad Institute of Harvard and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
Nature 468:968-72. 2010..B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials...
- Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert
Institute Gustave, Roussy, Villejuif, France
N Engl J Med 364:2517-26. 2011..100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously ..
- A landscape of driver mutations in melanomaEran Hodis
The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
Cell 150:251-63. 2012Despite recent insights into melanoma genetics, systematic surveys for driver mutations are challenged by an abundance of passenger mutations caused by carcinogenic UV light exposure...
- Highly recurrent TERT promoter mutations in human melanomaFranklin W Huang
Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
Science 339:957-9. 2013..Thus, somatic mutations in regulatory regions of the genome may represent an important tumorigenic mechanism...
- Efficient tumour formation by single human melanoma cellsElsa Quintana
Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
Nature 456:593-8. 2008..Studies on diverse cancers, including melanoma, have indicated that only rare human cancer cells (0.1-0...
- Improved survival with ipilimumab in patients with metastatic melanomaF Stephen Hodi
Dana Farber Cancer Institute, Boston, MA 02115, USA
N Engl J Med 363:711-23. 2010An improvement in overall survival among patients with metastatic melanoma has been an elusive goal...
- Final version of 2009 AJCC melanoma staging and classificationCharles M Balch
Department of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
J Clin Oncol 27:6199-206. 2009To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database.
- Identification of cells initiating human melanomasTobias Schatton
Transplantation Research Center, Children s Hospital Boston and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nature 451:345-9. 2008..Here we identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by expression of the chemoresistance mediator ABCB5 (refs 7, 8) and show that ..
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild
University Hospital, Schleswig Holstein, Department of Dermatology, Kiel, Germany
Lancet 380:358-65. 2012..has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients with BRAF(V600E)-mutated metastatic melanoma.
- Nivolumab plus ipilimumab in advanced melanomaJedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
N Engl J Med 369:122-33. 2013In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor ..
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapySteven A Rosenberg
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 17:4550-7. 2011Most treatments for patients with metastatic melanoma have a low rate of complete regression and thus overall survival in these patients is poor...
- A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growthAlexander Roesch
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Cell 141:583-94. 2010..JARID1B (KDM5B/PLU-1/RBP2-H1) as a biomarker, we have characterized a small subpopulation of slow-cycling melanoma cells that cycle with doubling times of >4 weeks within the rapidly proliferating main population...
- Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanomaChristine Guo Lian
Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cell 150:1135-46. 2012..Here, we report that "loss of 5-hmC" is an epigenetic hallmark of melanoma, with diagnostic and prognostic implications...
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Lancet 379:1893-901. 2012..We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases.
- BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanomaMaria Colombino
Istituto Chimica Biomolecolare, Consiglio Nazionaledelle Ricerche, Italy
J Clin Oncol 30:2522-9. 2012The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the prevalence and distribution of mutations in these genes in different melanoma tissues.
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long
Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
Lancet Oncol 13:1087-95. 2012Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17-22 weeks...
- Cancer regression in patients after transfer of genetically engineered lymphocytesRichard A Morgan
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
Science 314:126-9. 2006..host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting...
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRAnirudh Prahallad
Division of Molecular Carcinogenesis, Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Nature 483:100-3. 2012..BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show ..
- Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, USA
N Engl J Med 367:107-14. 2012Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-..
- Rac activation and inactivation control plasticity of tumor cell movementVictoria Sanz-Moreno
Institute of Cancer Research, Cancer Research UK Centre for Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
Cell 135:510-23. 2008..These two modes of cell movement are interconvertible. We show that mesenchymal-type movement in melanoma cells is driven by activation of the GTPase Rac through a complex containing NEDD9, a recently identified ..
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid
Angeles Clinic and Research Institute, Los Angeles, CA, USA
N Engl J Med 369:134-44. 2013..We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Nature 480:387-90. 2011....
- A tumorigenic subpopulation with stem cell properties in melanomasDong Fang
Program of Molecular and Cellular Oncogenesis, The Wistar Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, PA 19104, USA
Cancer Res 65:9328-37. 2005..Individual cells from melanoma spheres (melanoma spheroid cells) could differentiate under appropriate conditions into multiple cell lineages, ..
- Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanomaMolly Yancovitz
Department of Dermatology, New York University Langone Medical Center, New York, New York, United States of America
PLoS ONE 7:e29336. 2012..the emergence of BRAF(V600E) as a therapeutic target, we investigated intra- and inter-tumor heterogeneity in melanoma using detection of the BRAF(V600E) mutation as a marker of clonality...
- Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFSonja J Heidorn
The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
Cell 140:209-21. 2010..BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice. Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression...
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patientsJulien Fourcade
Department of Medicine and Division of Hematology Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
J Exp Med 207:2175-86. 2010..In patients with advanced melanoma, we have previously shown that the cancer-germline antigen NY-ESO-1 stimulates spontaneous NY-ESO-1-specific CD8(+..
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaMichael Krauthammer
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
Nat Genet 44:1006-14. 2012We characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas...
- Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KJessie Villanueva
The Wistar Institute, Philadelphia, PA 19104, USA
Cancer Cell 18:683-95. 2010BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge...
- Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemC M Balch
Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Clin Oncol 19:3622-34. 2001..recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,..
- Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensMark E Dudley
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
J Clin Oncol 26:5233-9. 2008The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%...
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METHector Peinado
Children s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, Cell and Developmental Biology, Weill Cornell Medical College, New York, New York, USA
Nat Med 18:883-91. 2012Tumor-derived exosomes are emerging mediators of tumorigenesis. We explored the function of melanoma-derived exosomes in the formation of primary tumors and metastases in mice and human subjects...
- Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organizedElsa Quintana
Howard Hughes Medical Institute
Cancer Cell 18:510-23. 2010We investigated whether melanoma is hierarchically organized into phenotypically distinct subpopulations of tumorigenic and nontumorigenic cells or whether most melanoma cells retain tumorigenic capacity, irrespective of their phenotype...
- From genes to drugs: targeted strategies for melanomaKeith T Flaherty
Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA
Nat Rev Cancer 12:349-61. 2012The past decade has revealed that melanoma is comprised of multiple subclasses that can be categorized on the basis of key features, including the clinical stage of disease, the oncogenic molecular 'drivers', the anatomical location or ..
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer
Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 28:3167-75. 2010..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
- Melanoma biology and new targeted therapyVanessa Gray-Schopfer
The Institute of Cancer Research, Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
Nature 445:851-7. 2007b>Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin...
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanomaSergey I Nikolaev
Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
Nat Genet 44:133-9. 2011We performed exome sequencing to detect somatic mutations in protein-coding regions in seven melanoma cell lines and donor-matched germline cells...
- Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingNikhil Wagle
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
J Clin Oncol 29:3085-96. 2011..RAF inhibition in BRAF-mutant melanoma exemplifies the promise and challenge of many targeted drugs; although response rates are high, resistance ..
- Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanomaMaría R Girotti
Signal Transduction Team, The Institute of Cancer Research, Royal Marsden Hospital, London, UK
Cancer Discov 3:158-67. 2013..inhibitor-mediated activation of EGFR-SFK-STAT3 signaling can mediate resistance in patients with BRAF-mutant melanoma. We describe 2 treatments that seem to overcome this resistance and could deliver therapeutic efficacy in ..
- Wnt5a signaling directly affects cell motility and invasion of metastatic melanomaAshani T Weeraratna
National Human Genome Research Institute, Cancer Genetics Branch, National Institutes of Health, Bethesda, MD 20892, USA
Cancer Cell 1:279-88. 2002Gene expression profiling identified human melanoma cells demonstrating increased cell motility and invasiveness. The gene WNT5A best determined in vitro invasive behavior...
- Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271Alexander D Boiko
Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, California 94304 5542, USA
Nature 466:133-7. 2010..Here we show that in melanomas, tumour stem cells (MTSCs, for melanoma tumour stem cells) can be isolated prospectively as a highly enriched CD271(+) MTSC population using a process ..
- Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen speciesRachel Sensenig
Department of Surgery, College of Medicine, Drexel University, Philadelphia, PA 19102, USA
Ann Biomed Eng 39:674-87. 2011..The purpose of this study was to evaluate the potential of DBD plasma to induce apoptosis in melanoma cells...
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanomaDouglas J Schwartzentruber
Indiana University Health Goshen Center for Cancer Care, Goshen, IN 46526, USA
N Engl J Med 364:2119-27. 2011..We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes...
- NRAS mutation status is an independent prognostic factor in metastatic melanomaJohn A Jakob
Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 118:4014-23. 2012There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS ..
- Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanomaSteven Anderson
Medical and Scientific Affairs, Roche Molecular Systems, Inc, 4300 Hacienda Dr, Pleasanton, CA 94588, USA
Arch Pathol Lab Med 136:1385-91. 2012..companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib.
- Requirement of vascular integrin alpha v beta 3 for angiogenesisP C Brooks
Department of Immunology, Scripps Research Institute, La Jolla, CA 92037
Science 264:569-71. 1994..v beta 3 blocked angiogenesis induced by basic fibroblast growth factor, tumor necrosis factor-alpha, and human melanoma fragments but had no effect on preexisting vessels...
- Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
N Engl J Med 366:925-31. 2012..We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy...
- Exome sequencing identifies GRIN2A as frequently mutated in melanomaXiaomu Wei
The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
Nat Genet 43:442-6. 2011The incidence of melanoma is increasing more than any other cancer, and knowledge of its genetic alterations is limited...
- A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanomaP van der Bruggen
Ludwig Institute for Cancer Research, Brussels, Belgium
Science 254:1643-7. 1991Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient...
- Tumor-specific Th17-polarized cells eradicate large established melanomaPawel Muranski
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
Blood 112:362-73. 2008..novel epitope in tyrosinase-related protein 1 (TRP-1), an antigen expressed by normal melanocytes and B16 murine melanoma. Cells could be robustly polarized into Th0, Th1, and Th17 subtypes in vitro, as evidenced by cytokine, chemokine,..
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Paul F Robbins
National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
J Clin Oncol 29:917-24. 2011..using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and ..
- BRAF targeted therapy changes the treatment paradigm in melanomaAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, and Jonsson Comprehensive Cancer Center at UCLA, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Nat Rev Clin Oncol 8:426-33. 2011After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon...
- Integrative analysis of the melanoma transcriptomeMichael F Berger
The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
Genome Res 20:413-27. 2010..of transcriptomic and structural genomic data, and we applied this approach to generate new insights into melanoma biology...
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai
Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
Proc Natl Acad Sci U S A 105:3041-6. 2008..In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-Raf(V600E)-positive cells...
- Braf(V600E) cooperates with Pten loss to induce metastatic melanomaDavid Dankort
Cancer Research Institute and Department of Cell and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA
Nat Genet 41:544-52. 2009Mutational activation of BRAF is the earliest and most common genetic alteration in human melanoma. To build a model of human melanoma, we generated mice with conditional melanocyte-specific expression of BRaf(V600E)...
- Adoptive cell therapy for the treatment of patients with metastatic melanomaSteven A Rosenberg
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA
Curr Opin Immunol 21:233-40. 2009Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating ..
- Frequent mutation of BAP1 in metastasizing uveal melanomasJ William Harbour
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
Science 330:1410-3. 2010..These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target.
- Somatic activation of KIT in distinct subtypes of melanomaJohn A Curtin
Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143 0808, USA
J Clin Oncol 24:4340-6. 2006..This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS.
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenLaura A Johnson
Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
Blood 114:535-46. 2009..mice and also conducted high-throughput screening of human lymphocytes to generate TCRs highly reactive to melanoma/melanocyte antigens...
- Increasing burden of melanoma in the United StatesEleni Linos
Northern California Cancer Center, Fremont, California, USA
J Invest Dermatol 129:1666-74. 2009It is controversial whether worldwide increases in melanoma incidence represent a true epidemic...
- SOX2 contributes to melanoma cell invasionSasha D Girouard
Program in Dermatopathology, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Lab Invest 92:362-70. 2012The mechanisms of melanoma invasion are poorly understood despite extensive inquiry...
- Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cellsAlexander Roesch
Department of Dermatology, The Saarland University Hospital, D 66421 Homburg Saar, Germany
Cancer Cell 23:811-25. 2013Despite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma are short-lived because of the acquisition of drug resistance...
- Apoptosis and melanoma chemoresistanceMaria S Soengas
Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 28109, USA
Oncogene 22:3138-51. 2003b>Melanoma is the most aggressive form of skin cancer and is notoriously resistant to all current modalities of cancer therapy...
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviCatherine D Van Raamsdonk
Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada
Nature 457:599-602. 2009..frequent somatic mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%)...
- Characterization of the Melanoma miRNAome by Deep SequencingMitchell S Stark
Oncogenomics Laboratory, Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia
PLoS ONE 5:e9685. 2010..Little is known about the repertoire and function of miRNAs in melanoma or the melanocytic lineage...
- Signatures of microRNAs and selected microRNA target genes in human melanomaDemetra Philippidou
Life Sciences Research Unit, University of Luxembourg, Freiburg, Germany
Cancer Res 70:4163-73. 2010..In this study, we investigated miRNA and miRNA target gene expression patterns in melanoma to identify candidate biomarkers for early and progressive disease...
- Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte functionAndrea Boni
Division of Surgical Oncology, Medical Oncology, and Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer Res 70:5213-9. 2010..BRAF/mitogen-activated protein kinase (MAPK) pathway is a promising new therapeutic approach for the treatment of melanoma. Treatment with selective BRAF inhibitors results in a high initial response rate but limited duration of ..
- miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 proteinAltaf A Dar
California Pacific Medical Center Research Institute, San Francisco, California 94107, USA
J Biol Chem 286:16606-14. 2011..Here, we report that expression of miR-205 is significantly suppressed in melanoma specimens when compared with nevi and is correlated inversely with melanoma progression...
- MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanomaLei Jin
Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei 230027, People s Republic of China
Proc Natl Acad Sci U S A 108:15840-5. 2011..undergoes inactivating mutations in many human cancers, but WT p53 is often expressed at high levels in melanoma, which, as judged from the malignant nature of the disease, fails to act as an effective tumor suppressor...
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin
University of Washington, Seattle, WA 98109, USA
Lancet Oncol 13:459-65. 2012Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab improves survival in patients with advanced melanoma...
- Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanomaJo Eyles
Singapore Immunology Network, BMSI, A STAR, Singapore
J Clin Invest 120:2030-9. 2010..Here, we have used a spontaneous mouse model of melanoma to investigate tumor cell dissemination and immune control of metastatic outgrowth...
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNallasivam Palanisamy
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA
Nat Med 16:793-8. 2010..rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF ..
- MelanomaArlo J Miller
Dermatopathology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
N Engl J Med 355:51-65. 2006
- PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionKim H T Paraiso
Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida, USA
Cancer Res 71:2750-60. 2011..covering all stages of melanocytic neoplasia (n = 192) revealed PTEN expression to be lost in >10% of all melanoma cases...
- A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinomaCorine Bertolotto
1 INSERM, U895 équipe 1, Equipe labélisée Ligue contre le cancer, C3M, 06204 Nice, France 2 Université of Nice Sophia Antipolis, UFR Medecine, 06204 Nice, France 3 Centre Hospitalier Universitaire de Nice, Service de Dermatologie, 06204 Nice, France 4
Nature 480:94-8. 2011So far, no common environmental and/or phenotypic factor has been associated with melanoma and renal cell carcinoma (RCC)...
- Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaJedd D Wolchok
Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 15:7412-20. 2009..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
- Mutations in GNA11 in uveal melanomaCatherine D Van Raamsdonk
Department of Medical Genetics, University of British Columbia, Vancouver, Canada
N Engl J Med 363:2191-9. 2010Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.
- In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanomaFlorian A Karreth
Cancer Genetics Program, Division of Genetics, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, MA 02215, USA
Cell 147:382-95. 2011..Loss of PTEN, a tumor suppressor regulated by ceRNA activity, frequently occurs in melanoma. Here, we report the discovery of significant enrichment of putative PTEN ceRNAs among genes whose loss ..
- A novel recurrent mutation in MITF predisposes to familial and sporadic melanomaSatoru Yokoyama
Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Massachusetts 02114, USA
Nature 480:99-103. 2011So far, two genes associated with familial melanoma have been identified, accounting for a minority of genetic risk in families...
- Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistanceHubing Shi
Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52 121 CHS, 10833 Le Conte Avenue, California 90095 1750, USA
Nat Commun 3:724. 2012The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy for melanoma patients...
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer
Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
J Clin Oncol 31:1767-74. 2013..effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib and ultimately to optimization of ..
- Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanomaJared J Gartner
National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 110:13481-6. 2013..We used whole-genome and -exome sequencing to identify somatic mutations in 29 melanoma samples...
- Sentinel-node biopsy or nodal observation in melanomaDonald L Morton
Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
N Engl J Med 355:1307-17. 2006We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.
- Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysisSimone Mocellin
Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
J Natl Cancer Inst 102:493-501. 2010..of interferon alpha (IFN-alpha) in the adjuvant setting improves disease-free survival (DFS) in patients with high-risk cutaneous melanoma. However, RCTs have yielded conflicting data on the effect of IFN-alpha on overall survival (OS).
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanomaIris Helfrich
Department of Dermatology, University Hospital Essen, Essen, Germany
J Exp Med 207:491-503. 2010..melanomas of MT/ret transgenic mice after using PTK787/ZK222584 for anti-VEGF therapy but also analyzed human melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment using bevacizumab...
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyK H T Paraiso
Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Br J Cancer 102:1724-30. 2010Resistance to BRAF inhibitors is an emerging problem in the melanoma field. Strategies to prevent and overcome resistance are urgently required.
- Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptorsTripti Singh
Department of Dermatology, University of Alabama at Birmingham, 35294, USA
Carcinogenesis 32:86-92. 2011b>Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize...
- Inhibition of mutated, activated BRAF in metastatic melanomaKeith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
N Engl J Med 363:809-19. 2010..The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease...
- Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanomaGeorgina V Long
Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
J Clin Oncol 29:1239-46. 2011To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome.
- Expression profiling reveals novel pathways in the transformation of melanocytes to melanomasKeith Hoek
Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520 8059, USA
Cancer Res 64:5270-82. 2004..were used to assess global differential gene expression comparing normal human melanocytes with six independent melanoma cell strains from advanced lesions...
- BRAF and RAS mutations in human lung cancer and melanomaMarcia S Brose
Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
Cancer Res 62:6997-7000. 2002..kinase pathway activation common in non-small cell lung carcinomas (NSCLCs) and to extend the initial findings in melanoma, we screened DNA from 179 NSCLCs and 35 melanomas for BRAF mutations (exons 11 and 15)...
- A comprehensive catalogue of somatic mutations from a human cancer genomeErin D Pleasance
Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
Nature 463:191-6. 2010..Here we have sequenced the genomes of a malignant melanoma and a lymphoblastoid cell line from the same person, providing the first comprehensive catalogue of somatic ..
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaTyler R Simpson
Department of Immunology, M D Anderson Cancer Center, Houston, TX 77030, USA
J Exp Med 210:1695-710. 2013..receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory ..
- Gene expression profiling of primary cutaneous melanoma and clinical outcomeVeronique Winnepenninckx
Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
J Natl Cancer Inst 98:472-82. 2006..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome ..
- THE AGRICULTURAL HEALTH STUDY - FIELD STATIONSCharles Lynch; Fiscal Year: 2010..cancer incidence overall, prostate cancer, colorectal cancer, pancreatic cancer, lunch cancer, breast cancer, and melanoma are now published. Analysis of NHL and leukemia is now underway...
- NIEHS SUPPORT OF THE AHS COHORT STUDY AT NCICharles Knott; Fiscal Year: 2010..cancer incidence overall, prostate cancer, colorectal cancer, pancreatic cancer, lunch cancer, breast cancer, and melanoma are now published. Analysis of NHL and leukemia is now underway...
- Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injuryMaria Lauda Tomasi; Fiscal Year: 2012..Furthermore, UBC9 is overexpressed in several malignancies, such as lung adenocarcinoma, ovarian carcinoma, and melanoma. Antagonizing UBC9 function in MCF-7 breast cancer cells transplanted in nude mice inhibited cell growth and ..
- Role of IKK in NSCLC: Modulation of SMRT and NF-kappaBMarty W Mayo; Fiscal Year: 2012Lung cancer is the number one cancer killer in the United States, exceeding breast, colorectal, prostate, and melanoma malignancies combined...
- Xianglin Shi; Fiscal Year: 2015..radiation (UV) is a complete environmental carcinogen and that repeated exposures can lead to the development of melanoma and nonmelanoma skin cancers...
- ANDREW GREGORY SIKORA; Fiscal Year: 2015..MDSC infiltrate solid tumors, including coetaneous melanoma, and potently inhibit anti-tumor T cell responses through a variety of mechanisms including production of nitric ..
- UV-induced and NOS-mediated Zn elevation, translation regulation and apoptosisShiyong Wu; Fiscal Year: 2012More than 1 million cases of nonmelanoma skin cancer and 59,600 cases of melanoma are diagnosed yearly in the United States, resulting in about 10,600 deaths (about 7,800 due to melanoma) in 2005...
- TAMARA G TERZIAN; Fiscal Year: 2016..Dr Terzian has been granted a training award in Immunodermatology on "The role of p53 pathway in melanoma" that will be completed in June 2011. She will be promoted to Instructor upon completion of the training grant...
- ERIC KIRK LAU; Fiscal Year: 2014..provided by applicant): Accounting for an estimated ~70,000 new diagnoses and ~8,800 deaths in 2011, malignant melanoma is the most lethal skin cancer, representing ~8% of total cancers cases in the United States...
- Imaging Nonlinear Absorption of Biomarkers for Improved Detection of MelanomaWarren S Warren; Fiscal Year: 2010..We desire to detect important biomarkers associated with the onset of skin cancers, with a particular emphasis on melanoma. Specifically, we will apply a novel imaging technology (transient absorption microscopy) to image melanins and ..
- Vernon K Sondak; Fiscal Year: 2016..AND CORES 12 PROJECT 1: Potentiating the Effects of Targeted and Cytotoxic Agents on Cell-Based Immunotherapy n Melanoma 12 PROJECT 2: Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma 16 PROJECT 3: Augmenting the ..
- MECHANISM OF DRUG TRANSPORT IN LUNG CANCER CELLSSanjay Awasthi; Fiscal Year: 2011..hypothesis, we have shown regression of established tumors upon Rlip-depletion or inhibition in syngeneic mouse melanoma (Cancer Res. 66:2354, 2006), as well as lung cancer xenografts...
- Parental age at birth and risk of adult-onset cancer in female offspringYani Lu; Fiscal Year: 2013..colon), 279 (rectal), 1031 (endometrial), 298 (thyroid), 195 (kidney), 486 (ovarian), 337 (pancreatic) and 761 (melanoma)...
- The lymph node microenvionment in tumor metastasisJudith A Varner; Fiscal Year: 2012..applicant): Lymph nodes are the initial sites of metastasis for most solid tumors, including breast carcinoma and melanoma. Progression from lymph node metastases to distant metastases is suggested by the clinical record as excision of ..
- Adam Lin; Fiscal Year: 2014..Peptides used in this proposal are from a model antigen (ovalbumin) and common melanoma antigens (gp100 and Trp-2)...
- TNF-Mediated Tumor Promotion: The Role of Vascular LeukocytesPampee P Young; Fiscal Year: 2011..that contributes directly to specific proangiogenic vascular leukocyte subpopulations within both breast and melanoma skin cancers...
- Tpl2 in Carcinogenesis-Related InflammationKATHLEEN LEIGH DECICCO-SKINNER; Fiscal Year: 2011DESCRIPTION (provided by applicant): Skin cancer, including both melanoma and non-melanoma forms, is the most common type of cancer, with more than two million new cases expected to be diagnosed in 2010...
- Wei Dai; Fiscal Year: 2016..cycle checkpoint protein, leading to unscheduled activation of anaphase promoting complex/cyclosome (APC/C) in melanoma and HeLa cells...
- Novel Glycosaminoglycan Ethers for Prevention of MetastasisAlana L Welm; Fiscal Year: 2011..of a SAGE in mice prevents implantation and lung metastasis at Day 28 after intravenous injection of B16 melanoma cells...
- Jacki Kornbluth; Fiscal Year: 2015..NKLAM KO mice also have substantially higher numbers of lung metastases compared with WT after injection with B16 melanoma cells and show greater dissemination of lymphoma cells to lymph nodes from the primary tumor site...
- A Validated Resource of Thyroid Cancer Cell Lines for Pathway DiscoveryJEFFREY ALLEN KNAUF; Fiscal Year: 2010..e. of a different tumor lineage including melanoma and colon cancer)...
- Immunomodulation in melanoma therapyNOAH A CRAFT; Fiscal Year: 2012..b>Melanoma is a common cancer and a leading cause of loss of productive years...
- Plexin signalling in melanocyte biology and melanoma progressionGlynis A Scott; Fiscal Year: 2013..Melanocytes, or their stem cells, are also progenitor cells for the most deadly of skin cancers, melanoma, which arises as a step wise progression from benign, to minimally invasive, to metastatic tumor ...
- Role of TRPM1 (Melastatin1) in the Biology of Human MelanocytesVijayasaradhi Setaluri; Fiscal Year: 2012..member of a novel family of TRP channel proteins known as TRPMs, was originally identified as suppressor of mouse melanoma metastasis. Independently, we identified TRPM1 as a gene induced in growth arrested human melanoma cells...
- Role of Natural Killer Lytic-Associated Molecule (NKLAM) in Natural Killer FunctiJacki Kornbluth; Fiscal Year: 2010..They also have higher numbers of lung metastases compared with wild type mice after injection with B16 melanoma cells. NKLAM is an E3 ubiquitin ligase, an enzyme involved in the process of protein ubiquitination...
- Pilot Study of Arsenic, UV and Melanoma in a Non-Hispanic White PopulationJanice W Yager; Fiscal Year: 2011..of whether past and present environmental arsenic exposure act together with UV exposure to impact risk of melanoma in the New Mexico non-Hispanic white population...
- Vasiliki Poulaki; Fiscal Year: 2016DESCRIPTION (provided by applicant): Uveal melanoma (UM) is the most common intraocular malignancy in adults and, despite successful local control, leads to substantial mortality due to early metastasis...
- Listeria-Based Therapeutic Cancer Vaccine for MelanomaDirk G Brockstedt; Fiscal Year: 2011DESCRIPTION (provided by applicant): Melanoma is one of the most rapidly growing cancers worldwide with an estimated 8,420 deaths and 62,480 new cases in the United States in 2008 alone...
- Autophagy in epidermal melanocyte: a protective or a destructive role?Vijayasaradhi Setaluri; Fiscal Year: 2013..skin photosensitivity, and gain of melanocytes due to unregulated proliferation as occurs in cutaneous melanoma could eventually lead to death...
- Andrzej T Slominski; Fiscal Year: 2015..g. vitiligo or hyperpigmentation), proliferative processes (including precancerous states, epidermal cancer or even melanoma), UVB-induced pathology, inflammatory dermatoses and skin aging.
- Jerry D Glickson; Fiscal Year: 2016DESCRIPTION (provided by applicant): Melanoma remains one of the deadliest of human cancers with no effective method for treating the disseminated disease...
- Steven P Stratton; Fiscal Year: 2015..One out of three new cancers is a skin cancer. More than 1 million cases of non-melanoma skin cancer (NMSC) (basal cell carcinoma [BCC] and squamous cell cancers [SCC]) occur annually...
- ATF2 in DNA damage response.ZE apos EV A RONAI; Fiscal Year: 2010..for its regulation of the cell cycle, growth control, apoptosis, and tumorigenicity in non transformed and in melanoma cell lines;(5) Determine changes in the skin and melanoma tumor formation and in rate of mutagenesis in mice ..
- John H Sampson; Fiscal Year: 2016..cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma. Glioblastoma (GBM) is uniformly lethal, and current therapy is non-specific and produces a median overall ..
- Nihal Ahmad; Fiscal Year: 2016DESCRIPTION (provided by applicant): Melanoma, one of the most notorious and lethal forms of skin cancer, remains resistant to available treatments. Therefore, novel target-based approaches are needed for the management of this neoplasm...
- Epidemiology of testicular cancer in the Utah populationMia Hashibe; Fiscal Year: 2012..has been used in various gene identifying and familial clustering studies for breast cancer, colorectal cancer, melanoma and prostate cancer, but this will be the first application of using this database for studying testicular cancer ..
- Biomarkers to Guide Treatment and Improve Survival in Oral/Oropharyngeal CancerThomas E Carey; Fiscal Year: 2012..These survival rates are poorer than those for lymphoma, breast cancer and malignant melanoma. Conventional treatments based on radical surgery and radiation are associated with profound functional morbidity ..
- JENNA GEDDES SWEENEY; Fiscal Year: 2015..Several groups have demonstrated that melanoma cells secrete an abundance of Gal-1...
- SPORE in Skin CancerMeenhard Herlyn; Fiscal Year: 2009..This SPORE is focused on major skin cancers: melanoma, cutaneous T cell lymphoma (CTCL) and squamous cell carcinoma (SCC)...
- Research and Mentoring on Energetic Factors and Cancer: Established InvestigatorLeslie Bernstein; Fiscal Year: 2013..endometrial, ovarian, lung, colon, pancreas, bladder, rectal and thyroid cancer, non-Hodgkin's lymphoma and melanoma. Dr...
- KAREN TARASZKA HASTINGS; Fiscal Year: 2015..presentation of tyrosinase-related protein 1 (TRP1), a clinically-relevant autoantigen in vitiligo and melanoma. We have developed a TRP1-specific T cell receptor transgenic mouse model in which skin-specific Treg cells ..
- NAC for melanoma chemopreventionDouglas Grossman; Fiscal Year: 2010DESCRIPTION (provided by applicant): Melanoma is a potentially fatal form of skin cancer that, under the influence of ultraviolet (UV) radiation, arises from isolated melanocytes or melanocytic neoplasms (moles or nevi)...
- Marianne Berwick; Fiscal Year: 2015DESCRIPTION (provided by applicant): This application - Melanoma Prevention: Using the Sun - is intended to forward and develop Dr. Berwick's career goals. These are three-fold...
- Hampton University Skin of Color Research Institute Skin of Color Symposium 2011:Meena Katdare; Fiscal Year: 2011..cutaneous lupus, melanocytic disorders, keloids/wound healing, aging, cutaneous T cell lymphoma, malignant melanoma, optical properties of skin and advanced imaging techniques in skin of color...
- Zhiguo Zhang; Fiscal Year: 2016..alkylating agent, methylating the N7 and O6 positions of guanine, and has been used for the treatment of GBM and melanoma. The therapeutic benefit of TMZ depends on its ability to damage DNA and trigger cell death...
- M ALANNA RUDDELL; Fiscal Year: 2014..diagnostic to assess metastatic potential and the need for adjuvant therapy in many human cancers, including melanoma, colon, breast, and head and neck cancers, suggesting that the lymph nodes are somehow involved in metastasis...
- BONNIE ELYSSA GOULDROTHBERG; Fiscal Year: 2014..cancer-related proteins using immunofluorescence-based immunohistochemical methods on a cohort of 192 primary melanoma patients, on executing multivariate statistical algorithms to develop a multi-marker prognostic model and ..
- Seth J Orlow; Fiscal Year: 2016..in genetic disorders such as oculocutaneous albinism (OCA), in autoimmune diseases such as vitiligo, and in melanoma, and may be a modifier locus for primary congenital glaucoma and macular degeneration in X-linked retinoschisis...
- Fluorescein for Sentinel Lymph Node DetectionJames M McGreevy; Fiscal Year: 2012..of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer...
- June K Robinson; Fiscal Year: 2014..therapy is associated with developing skin cancer, especially squamous cell carcinoma (SCC) and malignant melanoma (MM)...
- OLGA VALERY VOLPERT; Fiscal Year: 2016DESCRIPTION (provided by applicant): Non-melanoma skin cancer (NMSC) is a major health problem in the United States, with over two million new cases diagnosed yearly, making it the most common cancer in this country (1)...
- Grant McFadden; Fiscal Year: 2014..successfully treat several diverse human brain cancers in xenografted immunodeficient mice and murine metastatic melanoma in immunocompetent mice...
- Gene Targeted Therapy of Brain TumorsJohn H Sampson; Fiscal Year: 2010..tumors remain the most common cause of cancer death among children and account for more deaths in adults than melanoma, and treatment for these tumors represents the most expensive medical therapy per quality-adjusted life-year ..
- Blood-based detection of BRAF DNA as a biomarker in metastatic melanoma patientsDavid Polsky; Fiscal Year: 2012DESCRIPTION (provided by applicant): Melanoma remains a highly morbid disease in the United States...
- Gender-Specific Role of Aim2 in Inflammation and AutoimmunityDivaker Choubey; Fiscal Year: 2011..Little is known about sensors for cytoplasmic DNA. Recently, Aim2 (absent in melanoma 2) and p202 proteins (encoded by the Aim2 and Ifi202 genes, respectively), members of the interferon (IFN)-..
- Development of a nanosecond pulsed electric field system to treat skin cancerRICHARD LEE NUCCITELLI; Fiscal Year: 2011..We have used the PulseCure to treat malignant melanoma and basal cell carcinoma in mice with very high efficacy...
- Invasive Behavior of Tumor Cells Producing Collagenase-1Constance E Brinckerhoff; Fiscal Year: 2013..This is accomplished by the collagenases, of which MMP-1 is the most ubiquitously expressed. Malignant melanoma is an aggressive cancer where MMP-1 contributes to an invasive phenotype and is associated with poor outcome...
- Andrew D Weinberg; Fiscal Year: 2014..that enhance T cell function in cancer patients have shown significant anti-tumor efficacy in refractory melanoma, prostate cancer and renal carcinoma...
- Targeting MCPyV to Overcome Immune Evasion in Merkel Cell CarcinomaPaul Nghiem; Fiscal Year: 2010..MCC is more than twice as likely to be lethal when compared to malignant melanoma. Furthermore, MCC has an increasing health impact as its reported incidence has more than tripled in the past 20 ..
- Wendy B Bollag; Fiscal Year: 2015DESCRIPTION (provided by applicant): The non-melanoma skin cancers (NMSCs), basal and squamous cell carcinoma, are the most common cancers, occurring more often than all cancers combined, with approximately 1 million new cases diagnosed ..
- Emily White; Fiscal Year: 2015..cancers expected by 2011), and the range of cancers that can be studied (prostate, breast, lung, colorectal, melanoma, bladder, blood/lymph) attract young investigators to work with her...
- John A D'Orazio; Fiscal Year: 2016..Loss-of-function polymorphisms in Mc1r correlate with fair skin and a high incidence of melanoma, while robust Mc1r function correlates with darker skin and UV resistance...
- Donald F Hunt; Fiscal Year: 2016..Presently, the most effective treatment for late stage metastatic melanoma involves adoptive cell therapy (ACT) with CD8+ T-cells...
- Cohort Study of Genetic Susceptibility to Cutaneous Malignant MelanomaJiali Han; Fiscal Year: 2010..evidence indicates that the repair of ultraviolet-induced DNA damage plays a critical role in protecting against melanoma;however, epidemiologic data are limited due to a limited number of genes and polymorphisms examined in initial ..
- TYPE IV COLLAGEN IN MELANOMA CELL INVASION & METASTASISJames McCarthy; Fiscal Year: 1999..Published and preliminary data are presented to demonstrate that melanoma cell adhesion and migration on type IV collagen is an important contributing factor to invasion in vitro...
- DNA-modulated release of drug from melanoma targeting NPKit Lam; Fiscal Year: 2009..of this research is to develop novel DNA-modulated drug release nanoparticles (DDRNP) that can target and treat melanoma, or other type of cancer, with high specificity...
- MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLSCraig Slingluff; Fiscal Year: 2009DESCRIPTION (provided by applicant): Peptide antigens recognized by human melanoma-reactive T cells can be incorporated in vaccines to induce immune responses against melanoma...
- MOLECULAR EPIDEMIOLOGY OF DNA REPAIR IN MELANOMAQingyi Wei; Fiscal Year: 2000Although sunlight exposure has been implicated in risk of cutaneous malignant melanoma (CMM), the exact role of ultraviolet light (UV in the etiology of CMM remains unclear. Host susceptibility to UV damage may also play an important role...
- INDUCTION OF MELANOMA WITH UV-ARonald Ley; Fiscal Year: 2000..objective of this research is to identify risk factors and underlying mechanisms for the induction cutaneous melanoma in humans. Specifically...
- PREDICTION AND MODIFICATION OF MELANOMA RISKDuPont Guerry; Fiscal Year: 2000b>Melanoma is a potentially lethal skin cancer. Its incidence and mortality rates are increasing faster than those of most other malignancies...
- Effect of UVA Irradiation on Melanocyte Stem Cells and Relationship to DevelopmenJAMES DOUGLAS HOERTER; Fiscal Year: 2012DESCRIPTION (provided by applicant): Melanoma is the most deadly form of human skin cancer. It is estimated that one American dies from melanoma every hour. However, melanoma is a highly curable disease when detected at early stages...
- Melanoma genes in high-risk twinsMyles Cockburn; Fiscal Year: 2006The presence of large and many nevi (moles) is the most important predictor of melanoma occurrence...
- MicroRNA Markers of Melanoma Metastasis in Lymph NodesSylvie Beaudenon; Fiscal Year: 2009Malignant melanoma is the least frequent but the most aggressive and deadliest form of skin cancer. Early detection and accurate staging are therefore crucial to ensure timely intervention and a good prognosis...
- Repair of Clustered DNA DamagesYoke W Kow; Fiscal Year: 2010b>Melanoma is the fifth and seventh most commonly diagnosed cancer in America men and women. The molecular and genetic basis for the formation of melanoma is still largely unclear...
- SPECIFIC ACTIVE IMMUNOTHERAPY OF HUMAN MELANOMAMalcolm Mitchell; Fiscal Year: 1993The goal of this proposal is to optimize specific active immunotherapy for melanoma. Towards that end, several aspects of the immunology of human melanoma will be studied, to determine the mechanisms by which some patients achieve ..